Table 6.
Clinical trials conducted for the management of skin cancer via nanotherapeutics (Source: ClinicalTrials.gov)
| Type of nanoparticle/ Therapeutic agent | Trial no | Title of the study | Condition | Phase | Country | Status | Start–End year |
|---|---|---|---|---|---|---|---|
| Liposome/ Interferon alfa-2b, Melanoma vaccine | NCT00004104 | Vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients with stage iii melanoma | Melanoma | Phase 2 | United States | Completed | 1998–2000 |
| Albumin-nanoparticle/ Paclitaxel (ABI-007) | NCT00081042 | ABI-007 in treating patients with inoperable locally recurrent or metastatic melanoma | Melanoma | Phase 2 | United States | Completed | 2004–2010 |
| Liposome/ Vincristine | NCT00145041 | Pharmacokinetic study of liposomal vincristine in patients with malignant melanoma & hepatic dysfunction | Melanoma | Phase 1 | United States | Completed | 2005–2007 |
| Albumin nanoparticle/ Paclitaxel (ABI-007) | NCT00404235 | Carboplatin and ABI-007 in treating patients with stage iv melanoma that cannot be removed by surgery | Melanoma | Phase 2 | United States | Completed | 2006–2010 |
| Albumin nanoparticle/ Paclitaxel | NCT00626405 | Bevacizumab and temozolomide or bevacizumab and paclitaxel albumin-stabilized nanoparticle formulation and carboplatin in treating patients with stage iv malignant melanoma that cannot be removed by surgery | Melanoma | Phase 2 | United States | Completed | 2008–2012 |
| Nanoparticle/ Docetaxel (BIND-014) | NCT01300533 | A study of BIND-014 given to patients with advanced or metastatic cancer | Skin cancer | Phase 1 | United States | Completed | 2011–2016 |
| Albumin nanoparticle/ Paclitaxel (Abraxane®) | NCT02158520 | nab-Paclitaxel and bevacizumab or ipilimumab as first-line therapy in treating patients with stage iv melanoma that cannot be removed by surgery | Melanoma | Phase 2 | United States | Completed | 2013–2019 |
| Albumin nanoparticle/ Paclitaxel (Abraxane®) | NCT02020707 | nab-Paclitaxel and bevacizumab in treating patients with unresectable stage iv melanoma or gynecological cancers | Melanoma | Phase 1 | United States | Recruiting | 2014-present |
| Albumin nanoparticle/ Paclitaxel (Abraxane®) | NCT02495896 | Recombinant EphB4-HSA fusion protein with standard chemotherapy regimens in treating patients with advanced or metastatic solid tumors | Head and neck squamous cell carcinoma | Phase 1 | United States | Active, not recruiting | 2015-present |
| Lipid nanoparticle/ mRNA-2752 | NCT03739931 | Dose escalation study of mRNA-2752 for intratumoral injection to participants in advanced malignancies | Melanoma | Phase 1 | United States, Israel | Recruiting | 2018-presnt |
| Topical nanoparticle ointment/ Paclitaxel (SOR007) | NCT03101358 | Study of topical SOR007 ointment for cutaneous metastases | Cutaneous metastases from non-melanoma cancer | Phase 1 & 2 | United States | Completed | 2018–2020 |
| Quantum dots | NCT04138342 | Topical fluorescent nanoparticles conjugated somatostatin analog for suppression and bioimaging breast cancer | Skin cancer | Phase 1 | Egypt, Saudi Arabia | Recruiting | 2019-present |
| Hafnium oxide-containing nanoparticle (NBTXR3) | NCT04834349 | Re-irradiation with NBTXR3 in combination with pembrolizumab for the treatment of inoperable locoregional recurrent head and neck squamous cell cancer | Head and neck squamous cell cancer | Phase 2 | United States | Active, not recruiting | 2021-present |
| Hafnium oxide-containing nanoparticle (NBTXR3) | NCT04862455 | NBTXR3, radiation therapy, and pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell cancer | Head and neck squamous cell carcinoma | Phase 2 | United States | Recruiting | 2021-presnt |
| Gadolinium-based nanoparticle | NCT04899908 | Stereotactic brain-directed radiation with or without AGuIX gadolinium-based nanoparticles in brain metastases | Metastasized melanoma | Phase 2 | United States | Recruiting | 2021-presnt |
| Liposome/ mRNA vaccine | NCT05264974 | Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy | Melanoma | Phase 1 | United States | Not yet recruiting | 2022-present |
| Hafnium oxide-containing nanoparticle (NBTXR3) | NCT04892173 | NBTXR3 with or without cetuximab in LA-HNSCC | Head and neck squamous cell carcinoma | Phase 3 | United States, Belgium, Bulgaria, France, Georgia, Spain | Recruiting | 2022-presnt |